About this podcast
Late-breaking advances in AI-enabled drug discovery, including news, research progress, market trends, and interviews
Episodes
The newest 20 of 79 episodes
- #80. The Agent Swarm · 19 min · Season 2 Episode 80Three fresh stories, one question: what happens when AI stops being a chatbot and starts doing the work of a lab? A swarm of AI agents reads millions of brain cells in minutes…
- #79. Can AI Drug the Undruggable? · 22 min · Season 2 Episode 79Three fresh stories, one question: what happens when AI stops needing a protein's 3D shape and starts working with biology as it actually behaves? A virtual cell trained on…
- #78. From Too Few to Too Many · 22 min · Season 2 Episode 78AI can now generate millions of molecules, thousands of drug targets, and entire scientific manuscripts in hours — but our capacity to validate any of it hasn't kept pace. This…
- #77. Virtual Biology's Reality Check · 26 min · Season 2 Episode 77Biohub's Virtual Biology Initiative just expanded to $1.8 billion — backed by the DOE, NIH, Google DeepMind, Isomorphic Labs, and Meta — to build the data foundations for…
- #76. AI's Phase III Moment · 22 minOn September 10, 2026, Insilico Medicine dosed the first patient in the Phase III GENESIS-IPF-3 trial of rentosertib (ISM001-055) for idiopathic pulmonary fibrosis - the first…
- #75. The AI Patent Landscape 2026 · 21 min · Season 2 Episode 32In this episode, we examine how AI-native biotechnology companies are reshaping drug discovery through the lens of their intellectual-property portfolios. The evidence suggests…
- #74. Is Drug Discovery AI Safe? · 21 min · Season 2 Episode 31In this podcast, we study how integrating agentic AI into autonomous wet labs promises rapid therapeutic innovation, while connecting autonomous models directly to physical lab…
- #73. The Triumph of Daraxonrasib · 19 min · Season 2 Episode 30For decades, KRAS stood as oncology’s archetypal “undruggable” target—a powerful cancer driver with no obvious pocket for conventional medicines to grasp. This episode explores…
- #72. 2026 Emerging Trends · 24 min · Season 2 Episode 29In this podcast, we show a pivotal shift in 2026 for AI drug discovery toward integrated, AI-native R&D systems that move beyond simple algorithmic tasks to form closed-loop…
- #71. Magic Wands · 24 min · Season 2 Episode 28In this episode, we critically examine whether AI drug discovery is solving the hardest problems in medicine—or simply making the easier ones faster. At the center of the…
- #70. Beyond AlphaFold · 23 min · Season 2 Episode 27In this episode, we venture beyond protein structure prediction into the messy, stochastic reality of modeling the virtual cell. We examine why biology still lacks an…
- #69. CollaboFest · 23 min · Season 2 Episode 26What if we could turn a spark of biological insight into a real-world, life-saving treatment? That is the core mission of CollaboFest, an innovative initiative designed to break…
- #68. Molecular Glues in Therapy · 22 min · Season 2 Episode 25In this episode, we explore the rapid evolution of molecular glues, a breakthrough in targeted protein degradation that stabilizes protein interactions to treat previously…
- #67. Does Size Matter? · 21 min · Season 2 Episode 24In this episode, we examine whether increasing the size and depth of neural networks truly enhances molecular property prediction compared to traditional machine learning. A…
- #66. Quantitative Systems Pharmacology · 26 min · Season 2 Episode 23In this episode, we explore the evolving role of Quantitative Systems Pharmacology (QSP) in drug development, particularly as a mechanistic alternative to traditional animal…
- #65. Orbiting around Big Pharma · 20 min · Season 2 Episode 22In this episode, we explore Lilly TuneLab as a major signal of where AI drug discovery may be heading: toward powerful platform ecosystems that combine proprietary pharmaceutical…
- #64. Foundation Models · 21 min · Season 2 Episode 21In this episode, we explore the surge of foundation models (FMs) within pharmaceutical research, noting that over 200 such models were published by early 2025. Unlike traditional…
- #63. The Era of NAMs · 21 min · Season 2 Episode 20This podcast explores the transformative shift toward New Approach Methodologies (NAMs), which utilize human-relevant experimental and computational systems to modernize drug…
- #62. Predicting Toxicity · 19 min · Season 2 Episode 19In this episode, we investigate the significant evolution of AI-driven toxicity prediction, detailing how the field has shifted from simple statistical models to sophisticated…
- #61. AI Era Evidence Flywheel · 22 min · Season 2 Episode 18In this episode, Dr. Jake Chen provides his narrative review and advocates for a fundamental shift in pharmaceutical research, moving away from inefficient trial-and-error toward…







